Psilocybin-Assisted Alcohol Use Disorder Outpatient Program
A structured addiction treatment service combining two supervised psilocybin sessions with motivational enhancement and cognitive-behavioral therapy, targeting AUD patients where the clinical trial cut heavy drinking days from 23.6% to 9.7% over 32 weeks.
Live prototype, embedded from its own deployment — interact right here.
Open full appConcept
A specialty addiction medicine service delivering psilocybin-assisted psychotherapy specifically for adults with alcohol use disorder. The treatment mirrors the protocol from [3]: two day-long psilocybin sessions (25–40 mg/70 kg, at weeks 4 and 8) embedded within 12 weeks of manualized psychotherapy combining motivational enhancement therapy and CBT, with 32 weeks of follow-up monitoring. Patients are screened to exclude major psychiatric contraindications consistent with trial exclusion criteria. Core service components include pre-treatment psychological preparation sessions, two supervised psilocybin dosing days in a supportive clinical setting, post-session integration therapy, and continuous alcohol use monitoring via timeline followback interview. The safety profile established across multiple psilocybin trials for MDD [0][4][5] and AUD [3]—consistently showing no serious adverse events under supervised conditions—makes the risk-benefit calculation favorable relative to existing pharmacotherapies with modest efficacy.
Why now
The double-blind RCT [3] demonstrated a statistically significant 13.9 percentage-point reduction in heavy drinking days over 32 weeks versus active placebo with identical therapy (P=.01). No currently approved AUD pharmacotherapy (naltrexone, acamprosate, disulfiram) achieves comparable effect sizes. With psilocybin advancing through FDA pathways and 12-month MDD follow-up data [5] showing durable effects and no drug-related serious adverse events, the evidence base is now sufficient to justify a clinical program. The US AUD population (~14.5 million) is large, systematically underserved, and increasingly open to novel modalities.
AI assessment
A clinically well-grounded AUD treatment concept with a specific RCT-validated protocol and real market need, but near-term commercial viability is severely constrained by federal Schedule I status and an immature regulatory framework.
- Evidence strength 4/5
- The AUD efficacy claim rests on one double-blind RCT (n=95, P=.01), which is real but thin as a single-trial finding; multiple independent MDD trials meaningfully corroborate the supervised-use safety profile, giving partial multi-source convergence.
- Market pull 4/5
- 14.5 million Americans with AUD, chronically underserved by existing pharmacotherapies with poor adherence and modest effect sizes, represents a large and commercially attractive addressable population — docked one point because federal Schedule I status and only two state-level therapeutic frameworks severely compress the near-term reachable market.
- Novelty & moat 3/5
- The commercial idea is a direct lift of an existing published protocol rather than a scientific or design innovation; the AUD application is less crowded than the MDD psilocybin space, but novelty is incremental rather than distinctive.
- Feasibility 2/5
- Operating legally requires either a DEA Schedule I researcher license, state-level therapeutic frameworks (currently only Oregon and Colorado), or FDA Breakthrough Therapy designation that has not yet been granted for AUD — the idea glosses over these structural barriers that make near-term clinical operation genuinely difficult rather than merely procedural.
- Wedge clarity 3/5
- Superior effect-size data versus approved pharmacotherapies is a credible differentiation argument, but the wedge depends entirely on regulatory access that doesn't yet exist at scale, and established academic medical centers already running psilocybin programs will be formidable first-movers.
- Simplicity / focus 4/5
- One indication, one well-specified protocol (two dosing days plus manualized psychotherapy), one patient population — appropriately focused without platform bloat.
Scored by AI against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity). A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Hazelden Betty Ford Foundationorganization
As the largest nonprofit addiction treatment network in the US, Hazelden Betty Ford could integrate this protocol into its existing evidence-based residential and outpatient programs, substantially improving outcomes for the AUD patients who cycle through repeated treatment episodes.
- American Addiction Centerscompany
AAC operates addiction treatment facilities nationwide and would benefit from a psilocybin-based protocol that outperforms current pharmacological standards, creating a differentiated clinical offering in a highly competitive market.
NIAAA funds AUD treatment research and would benefit from a clinical program that operationalizes the [3] trial findings, generates real-world evidence, and informs regulatory strategy for psilocybin in AUD.
- Shatterprooforganization
Shatterproof drives adoption of evidence-based addiction treatment quality standards nationwide and could champion psilocybin-assisted AUD therapy as a benchmark protocol given the strong RCT evidence.
Research it builds on
- Trial of Psilocybin versus Escitalopram for DepressionRobin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts et al. · 2021 · 1378 citationsAll ideas from this paper →
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderMichael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. · 2022 · 670 citationsAll ideas from this paper →
- Single-Dose Psilocybin Treatment for Major Depressive DisorderCharles L. Raison, Gerard Sanacora, Joshua Woolley et al. · 2023 · 496 citationsAll ideas from this paper →
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-upNatalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. · 2022 · 419 citationsAll ideas from this paper →
Related ideas
- Psychedelic-Integrated Therapy Certification for Clinicians
A professional certification program for clinicians to deliver psychedelic-assisted therapy, focusing on the critical preparatory and integrative psychological frameworks. The program emphasizes ethical safeguards and personalized care to manage the heightened suggestibility and vulnerability of patients during psychedelic experiences.
same research - MDMA-Assisted PTSD Therapy Network for Veterans and First Responders
A dedicated clinic network delivering the phase-3-validated MDMA-assisted therapy protocol for severe, treatment-resistant PTSD in veterans and first responders, targeting patients with comorbidities who fail existing treatments.
- FishParasiteScan: AI-Powered Parasite Surveillance Platform for Tropical Aquaculture
A field-deployable diagnostic and monitoring service that combines rapid parasite identification with seasonal risk forecasting, helping freshwater fish farms and fisheries in tropical regions detect and control parasitic infections before they spread.
- MicroScope Submit: AI-Powered Manuscript Triage & Scope-Matching Platform for Microbiology Journals
A SaaS tool that automatically reads incoming microbiology manuscripts, checks whether they fit a journal's stated scope, suggests qualified reviewers, and routes papers to the right section — cutting editorial workload for multidisciplinary journals.
- AlignerSafe: Material Leachable Screening & Wear-Exposure Label
A standardized testing and certification service that quantifies leachable compounds from aligner materials and gives clinicians a cumulative-exposure safety profile per product.
- Intracellular 5-HT2AR Location-Bias Drug Screening Assay
A preclinical assay service that distinguishes between compounds activating cell-surface versus intracellular 5-HT2A receptors. This allows drug developers to isolate neuroplasticity-promoting effects from hallucinogenic activity, targeting a specific subcellular receptor pool.